Antidepressants Not Associated with Bruxism
Bupropion, mirtazapine, citalopram, escitalopram, fluoxetine, and sertraline appear to have the lowest association with bruxism among antidepressants, while paroxetine, venlafaxine, and duloxetine are most strongly linked to this adverse effect.
High-Risk Antidepressants for Bruxism
The evidence consistently identifies specific antidepressants with the strongest association to bruxism:
Paroxetine shows the highest risk across multiple studies, with odds ratios of 3.63 for sleep bruxism and documented increases in both awake and sleep bruxism 1, 2, 3.
Venlafaxine (SNRI) demonstrates significant association with bruxism (OR = 2.28) and was among the most commonly reported offending agents in case reports 4, 1, 3.
Duloxetine (SNRI) is associated with increased sleep bruxism risk (OR = 2.16), with specific evidence showing increased sleep bruxism by the fourth week of treatment 1, 2, 3.
Lower-Risk Antidepressant Options
Based on the available evidence, the following antidepressants show no increased odds of bruxism:
SSRIs with Lower Risk:
Citalopram - No increased odds of sleep bruxism observed in cross-sectional studies 1. However, one case report documents transmission through breast milk causing infant bruxism, suggesting the drug itself has bruxism potential 5.
Escitalopram - No increased odds of sleep bruxism in adult populations 1, 6.
Fluoxetine - Despite being commonly reported in case series, cross-sectional studies found no increased odds of sleep bruxism 4, 1.
Sertraline - No increased odds of sleep bruxism despite being frequently mentioned in case reports 4, 1, 6.
Non-SSRI Antidepressants with Lower Risk:
Mirtazapine - No increased odds of sleep bruxism observed 1.
Bupropion - Not specifically studied for bruxism association, but notably has a different mechanism of action (dopamine/norepinephrine reuptake inhibitor) and is associated with lower rates of other adverse effects like sexual dysfunction 7.
Clinical Algorithm for Antidepressant Selection in Bruxism-Prone Patients
Step 1: If the patient has pre-existing bruxism or TMD, avoid paroxetine, venlafaxine, and duloxetine as first-line agents 1, 2, 3, 8.
Step 2: Consider bupropion, mirtazapine, escitalopram, or citalopram as preferred first-line options based on the patient's depression/anxiety profile and other comorbidities 1.
Step 3: If bruxism develops within 3-4 weeks of starting any antidepressant, consider three management options 4:
- Add buspirone (most effective adjunctive treatment)
- Switch to a lower-risk antidepressant from the list above
- Reduce the dose if clinically feasible
Step 4: Monitor specifically for jaw clenching, tooth grinding (especially nocturnal), jaw pain, and temporomandibular symptoms within the first month of treatment 4, 3.
Important Clinical Caveats
Gender considerations: Bruxism from antidepressants occurs more frequently in women, and sleep bruxism specifically increased in males by the fourth week of treatment 2, 3.
Time course: Symptoms typically begin within 3-4 weeks of medication initiation and resolve within 3-4 weeks of discontinuation or intervention 4, 2.
Discrepancy in evidence: There is a notable disconnect between case reports (which frequently implicate fluoxetine and sertraline) and cross-sectional studies (which show no increased odds for these agents) 4, 1. This suggests these medications may cause bruxism in susceptible individuals but not at a population level.
Buspirone as rescue: Dopamine agonists and buspirone are the most effective medications to treat SSRI-induced bruxism without discontinuing the antidepressant 8.
Family history matters: Patients with a family history of teeth grinding are at higher risk for antidepressant-induced bruxism 3.